Xarelto vs Vascepa
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Xarelto | US Vascepa | |
|---|---|---|
| Generic name | rivaroxaban | icosapent ethyl |
| Drug class | Factor Xa Inhibitor | Omega-3 Fatty Acid (EPA) |
| Treats | Blood clots, atrial fibrillation | High triglycerides, cardiovascular risk reduction |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Janssen/Bayer | Amarin |
| Year approved | 2011 | 2012 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $210M | $90M |
| Common side effects | Serious bleeding risk, Bruising, Prolonged bleeding, Spinal/epidural blood clots | Atrial fibrillation, Bleeding risk, Joint pain, Swelling |
Frequently asked questions
Is Xarelto or Vascepa better?
Neither is universally "better." Xarelto (rivaroxaban) and Vascepa (icosapent ethyl) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xarelto and Vascepa?
Xarelto is a Factor Xa Inhibitor made by Janssen/Bayer, while Vascepa is a Omega-3 Fatty Acid (EPA) made by Amarin. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xarelto has the larger estimated TV advertising budget of the two.